The role of pathological tau in synaptic dysfunction in Alzheimer's diseases

Transl Neurodegener. 2021 Nov 10;10(1):45. doi: 10.1186/s40035-021-00270-1.

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive decline, accompanied by amyloid-β (Aβ) overload and hyperphosphorylated tau accumulation in the brain. Synaptic dysfunction, an important pathological hallmark in AD, is recognized as the main cause of the cognitive impairments. Accumulating evidence suggests that synaptic dysfunction could be an early pathological event in AD. Pathological tau, which is detached from axonal microtubules and mislocalized into pre- and postsynaptic neuronal compartments, is suggested to induce synaptic dysfunction in several ways, including reducing mobility and release of presynaptic vesicles, decreasing glutamatergic receptors, impairing the maturation of dendritic spines at postsynaptic terminals, disrupting mitochondrial transport and function in synapses, and promoting the phagocytosis of synapses by microglia. Here, we review the current understanding of how pathological tau mediates synaptic dysfunction and contributes to cognitive decline in AD. We propose that elucidating the mechanism by which pathological tau impairs synaptic function is essential for exploring novel therapeutic strategies for AD.

Keywords: Alzheimer’s disease; Pathological tau; Synaptic dysfunction; Synaptic plasticity.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alzheimer Disease* / pathology
  • Amyloid beta-Peptides
  • Humans
  • Neurodegenerative Diseases*
  • Synapses / pathology
  • tau Proteins

Substances

  • Amyloid beta-Peptides
  • tau Proteins